March 11, 2025
eMedClub News
Today, ROC ROCK Biotechnology announced its successful completion ofTens of Millions of RMB in Pre-A+ Round Financing, this round of financing was solely invested by Qingdao Yinghai Antai Equity Investment Partnership (Limited Partnership), and the proceeds willTo further accelerate the clinical trials and commercialization process of the company's multiple products under developmentPrior to this, ROC ROCK Biotechnology successfully secured angel round funding led by Destiny Capital and Pre-A round funding led by Huizhu Medical.Total financing nearly 100 million yuan。ROC ROCK Biotechnology was founded in 2021, isThe world's only company with a technology platform that integrates live cell factors, gene editing, biomaterials, and synthetic biology-driven engineered macrophages.The company focuses on macrophage therapy.Tumors and Chronic DiseasesDevelopment and clinical application in the field of diseases, actively promoting the research and development as well as industrialization of Chimeric Antigen Receptor Macrophages (CAR-M).ROC ROCK Biotechnology has establishedThe four major platforms: Macrophage-specific CAR design technology platform, Macrophage optimization culture technology platform, Monocyte rapid infection and culture technology platform, and Macrophage-specific virus modification technology platform..Relying on itsExtensive experience accumulated in macrophage engineering, bioinformatics analysis, and immune cell transdifferentiation.Currently advancing nine CAR-M cell therapy pipelines through multi-center collaborations with multiple institutions globally.
▲ Company's R&D Pipeline Diagram
● HER2-targeted solid tumor pipeline: Clinical research was initiated at the Affiliated Hospital of Xuzhou Medical University in 2023, with the first patient enrolled in December of the same year. By the end of 2024, a total of 7 patients have been enrolled.In 2025, the focus will be on screening HER2+++ patients with peritoneal metastasis.Accelerate the advancement to the registration clinical stage; Synchronous completion of the ethics approval at Jinan Junxin Tumor Hospital, currently in the process of somatic cell record filing, plannedThe first enrollment at this center will be achieved in June 2025.。
● C-MET Target Pancreatic Cancer Pipeline: Ethical approval has been obtained from Peking Union Medical College Hospital, and the somatic cell filing process is proceeding in an orderly manner, with plans to...June 2025Initiate the first patient enrollment.
● Prostate Cancer Pipeline: Project approval completed at a large hospital in Suzhou City, Jiangsu Province, by the end of 2024. Currently in the ethical review stage, expectedComplete 3-5 cases by 2025Patient Enrollment.
Among them, the lead pipeline RR-M01 injection of ROC ROCK Biotechnology is a product meticulously developed for solid tumors.Third-generation CAR-M targeting HER2The proposed indications for development include HER2-positive recurrent/refractory solid tumors such as ovarian cancer, gastric cancer, breast cancer, cervical cancer, endometrial cancer, lung cancer, and pancreatic cancer.
With its safety, uniqueness, and maturity, it successfully entered the IIT clinical research phase in May 2023. Not only has it achieved full independent research and development and 100% localization in China in terms of technology, but it is also...The World's First Third-Generation CAR-M to Enter the IIT StageGiven that RR-M01 injection has demonstrated higher efficacy and lower side effects in preclinical studies, the company plans to formally submit an application to the regulatory authorities this year, with expectations to obtain approval by 2026.
It is reported that ROC ROCK Biotechnology is dedicated to focusing on cell drugs targeting solid tumors.Successfully launch 2 innovative drugs within 5-6 years, enabling China to be at the forefront globally in the field of macrophage therapy for solid tumors, becoming a leader in CAR-M, and relentlessly striving to extend the lifespan of each solid tumor patient by 24 years.
Sun Yuhao, the investment director of Yinghai Antai, stated: As an investment institution focused on equity investment, Yinghai Antai's capital injection this time willAccelerate the IND submission process for ROC ROCK Biotechnology's core pipeline RR-M01, and provide strong support for multi-center clinical research on pipelines such as C-MET targeted pancreatic cancer.The investors value not only ROC ROCK Biotechnology's globally leading CAR-M technology platform and nine differentiated pipeline layouts, but also the team's twenty years of technical accumulation in the macrophage field and precise clinical advancement capabilities.Yin Xiushan, Chairman of ROC ROCK Biotechnology, stated: Solid tumors and chronic diseases are two major global health challenges. Macrophages hold tremendous potential and unique advantages in addressing these areas. As a leader in macrophage drug development, ROC ROCK Biotechnology has over 20 years of deep expertise in the macrophage field, consistently focusing on fundamental technological innovation and leveraging its platform to accelerate the clinical advancement of its pipeline.This funding will support our IND application for the M01 pipeline this year, as well as the launch of a clinical trial targeting pancreatic cancer in collaboration with Xiehe. Meanwhile, the macrophage candidate drugs targeting liver and lung fibrosis are also proceeding smoothly.。It is worth mentioning that, on June 14-15, 2024, during the 2024 IBI EXPO Annual Biomedical Innovation Top 50 Innovative Companies selection, ROC ROCK Biotechnology was named one of the most innovative companies on the Star Shine List for its groundbreaking advancements in CAR-M cell therapy technology.
1. ROC ROCK Biotechnology Official Website
Welcome everyone to register for the 2026 IBI EXPO conference.
Registration and Event Inquiry
IBI EXPO 2026 (4th) Biopharmaceutical Innovation Industry ConferenceWill beMarch 2026InHangzhouGrandly Held.The conference will invite300+Guest Speaker, Opening30+Field Forum Activities, LinkagePharmaceutical companies, research institutions, clinical resources, supply chain enterprises, investment and financing institutions, park governmentsBy leveraging multiple forces, we can drive the transformation of cutting-edge innovations from scientific research to industrial applications, injecting a source of development into the biopharmaceutical market.
Free Participation:Teacher Yang 15517201185
Free Exhibition:Teacher Yuan 15572286596
Speech & Media：Teacher Wang 18717836231
Click"Read the original text"Lock in Early Bird DiscountsStatement and Copyright Notice
Disclaimer: This article aims to convey industry development information and explore the frontier progress of biomedicine. The content of the article represents the author's viewpoint and does not represent the position of EMedClub, nor does it constitute any value judgment, investment advice, or medical guidance. If necessary, please consult a professional for investment or visit a regular hospital for medical advice.
Copyright Statement:Welcome to share the article on your personal Moments. Unauthorized media or institutions are prohibited from reprinting the article in any form on other platforms. If you need to reprint, please leave a message below the article to obtain authorization.
DianDian "Share”、“Like"And"In View"，Give me a little recharge~
